A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

PHASE4RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
BIOLOGICAL

Efgartigimod PH20 SC

Subcutaneous injection of efgartigimod PH20 SC

Trial Locations (13)

20010

RECRUITING

MedStar Washington Hospital Center, Washington D.C.

21216

RECRUITING

Horizon Clinical Research: Gill Neuroscience, Cypress

27607

RECRUITING

Velocity Clinical Research, Raleigh

32751

RECRUITING

Neurology Associates PA, Maitland

33180

RECRUITING

Visionary Investigators Network, Miami

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

37403

RECRUITING

Erlanger Neuroscience Institute, Chattanooga

48170

RECRUITING

SRI International - ClinEdge, Plymouth

60611

RECRUITING

Northwestern Memorial Hospital, Chicago

70508

RECRUITING

Velocity Clinical Research, Lafayette

75251

RECRUITING

Cedar Health Research - Dallas, Dallas

77429

RECRUITING

Northwest Houston Neurology - Cypress, Cypress

78759

RECRUITING

National Neuromuscular Research Institute, Austin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

argenx

INDUSTRY

NCT06637072 - A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC | Biotech Hunter | Biotech Hunter